Dopamine-induced oxidative stress in neurons with glutathione deficit: Implication for schizophrenia

Schizophrenia Research

Volumn 62, Issue 3, 2003, Pages 213-224

  Grima, Gilbert ^a   Benz, Beatrix ^a   Parpura, Vladimir ^b   Cuénod, Michel ^a   Do, Kim Q ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Connectivity; Dendritic spines; Dopamine; Glutathione; Oxidative stress

Indexed keywords

1,4 BENZOQUINONE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; ETACRYNIC ACID; GLUTATHIONE; SEMIQUINONE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CEREBROSPINAL FLUID; CONJUGATION; CONTROLLED STUDY; DENDRITIC SPINE; DOPAMINERGIC SYSTEM; HYPOTHESIS; IN VIVO STUDY; MEMBRANE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NERVE CELL; NERVE CELL CULTURE; NERVE ENDING; NONHUMAN; OXIDATIVE STRESS; PEROXIDATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCHIZOPHRENIA;

EID: 0037783987     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00405-X     Document Type: Article

References (80)

1. Ahokas J.T., Nicholls F.A., Ravenscroft P.J., Emmerson B.T. Inhibition of purified rat liver glutathione S-transferase isozymes by diuretic drugs. Biochem. Pharmacol. 34:1985;2157-2161.
2. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Res. Brain Res. Rev. 31:2000;106-112.
3. Ankarcrona M., Dypbukt J.M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S.A.et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 15:1995;961-973.
4. Baez S., Segura-Aguilar J., Widersten M., Johansson A.S., Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324:1997;25-28.
5. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64:1995;718-723.
6. Bennett C.N., Horrobin D.F. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukot. Essent. Fat. Acids. 63:2000;47-59.
7. Berman S.B., Hastings T.G. Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J. Neurochem. 69:1997;1185-1195.
8. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73:1999;1127-1137.
9. Berman S.B., Zigmond M.J., Hastings T.G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67:1996;593-600.
10. Bertolino A., Esposito G., Callicott J.H., Mattay V.S., van Horn J.D., Frank J.A., Berman K.F., Weinberger D.R. Specific relationship between prefrontal neuronal N-acetyl-aspartate and activation of the working memory cortical network in schizophrenia. Am. J. Psychiatry. 157:2000;26-33.
11. Bloom F.E. Advancing a neurodevelopmental origin for schizophrenia. Arch. Gen. Psychiatry. 50:1993;224-227.
12. 2: formation of epoxy- and hydroxyquinone adducts and electronically excited states. Basic Life Sci. 49:1988;81-86.
13. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Bernstein D., Yolken R.H. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry. 58:2001;1032-1037.
14. Choi J., Liu R.M., Kundu R.K., Sangiorgi F., Wu W., Maxson R.et al. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J. Biol. Chem. 275:2000;3693-3698.
15. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. N. Y. Acad. Sci. 899:2000;112-120.
16. Cooper A.J.L. Glutathione in the brain: disorders of glutathione metabolism. Rosenberg R.N., Prusiner S.B., Di Mauro S., Bardie R.L. The Molecular and Genetic Basis of Neurological Disease. 2nd ed. 1997;1195-1230 Butterworth-Heinemann, Boston.
17. Dhanbhoora C.M., Babson J.R. Thiol depletion induces lethal cell injury in cultured cardiomyocytes. Arch. Biochem. Biophys. 293:1992;130-139.
18. Do K.Q., Lauer C.J., Schreiber W., Zollinger M., Gutteck Amsler U., Cuenod M.et al. Gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J. Neurochem. 65:1995;2652-2662.
19. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D.et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 12:2000;3721-3728.
20. Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 62:2000;649-671.
21. Fahey R.C., Newton G.L. Determination of low-molecular-weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. Methods Enzymol. 143:1987;85-96.
22. Fernandez-Checa J.C., Kaplowitz N. The use of monochlorobimane to determine hepatic GSH levels and synthesis. Anal. Biochem. 190:1990;212-219.
23. Garey L.J., Ong W.Y., Patel T.S., Kanani A., Mortimer A.M., Barnes T.R.E.et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry. 65:1998;446-453.
24. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 57:2000;65-73.
25. Goldman-Rakic P.S. Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory. Carroll B.J., Barrrett J.E. Psychopathology and the Brain. 1991;1-23 Raven Press, New York.
26. Goldman-Rakic P.S., Leranth C., Williams S.M., Mons N., Geffard M. Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 86:1989;9015-9019.
27. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
28. Grima G., Benz B., Do K.Q. Glutamate-induced release of the nitric oxide precursor, arginine, from glial cells. Eur. J. Neurosci. 9:1997;2248-2258.
29. Halliwell B., Gutteridge J.C. Free Radicals in Biology and Medicine. 1998;Oxford Univ. Press, London.
30. Hammond C.L., Lee T.K., Ballatori N. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J. Hepatol. 34:2001;946-954.
31. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
32. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1956-1961.
33. Heales S.J., Davies S.E., Bates T.E., Clark J.B. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem. Res. 20:1995;31-38.
34. 2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem. J. 281:1992;627-630.
35. Huang J., Philbert M.A. Cellular responses of cultured cerebellar astrocytes to ethacrynic acid-induced perturbation of subcellular glutathione homeostasis. Brain Res. 711:1996;184-192.
36. Jain A., Martensson J., Stole E., Auld P.A., Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc. Natl. Acad. Sci. U. S. A. 88:1991;1913-1917.
37. Janaky R., Ogita K., Pasqualotto B.A., Bains J.S., Oja S.S., Yoneda Y.et al. Glutathione and signal transduction in the mammalian CNS. J. Neurochem. 73:1999;889-902.
38. Kohr G., Eckardt S., Luddens H., Monyer H., Seeburg P.H. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron. 12:1994;1031-1040.
39. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D.et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
40. LaVoie M.J., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19:1999;1484-1491.
41. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron. 28:2000;325-334.
42. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 19:1996;1-17.
43. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry. 43:1998;674-679.
44. 2+ mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. U. S. A. 87:1990;2196-2200.
45. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation, monoamine oxidase activity to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36:1981;589-593.
46. Meredith M.J., Reed D.J. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J. Biol. Chem. 257:1982;3747-3753.
47. Meyer A.J., Fricker M.D. Direct measurement of glutathione in epidermal cells of intact Arabidopsis roots by two-photon laser scanning microscopy. J. Microsc. 198:2000;174-181.
48. Michel P.P., Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26:1990;428-435.
49. Morikawa N., Nakagawa-Hattori Y., Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. J. Neurochem. 66:1996;1174-1181.
50. Murphy D.D., Segal M. Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J. Neurosci. 16:1996;4059-4068.
51. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants. Exp. Neurol. 141:1996;32-39.
52. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry. 47:1990;1023-1028.
53. Papa M., Bundman M.C., Greenberger V., Segal M. Morphological analysis of dendritic spine development in primary cultures of hippocampal neurons. J. Neurosci. 15:1995;1-11.
54. Parnas J., Bovet P., Innocenti G.M. Schizophrenic trait features, binding, and cortico-cortical connectivity: a neurodevelopmental pathogenetic hypothesis. Neurol. Psychiatry Brain Res. 4:1996;185-196.
55. Pearce B.D. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol. Psychiatry. 6:2001;634-646.
56. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48:1991;563-568.
57. Piani D., Frei K., Do K.Q., Cuenod M., Fontana A. Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci. Lett. 133:1991;159-162.
58. Popken G.J., Bunney W.E. Jr., Potkin S.G., Jones E.G. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9276-9280.
59. Pou S., Pou W.S., Bredt D.S., Snyder S.H., Rosen G.M. Generation of superoxide by purified brain nitric oxide synthase. J. Biol. Chem. 267:1992;24173-24176.
60. Rabinovic A.D., Hastings T.G. Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 71:1998;2071-2078.
61. Ross D., Thor H., Orrenius S., Moldeus P. Interaction of menadione, 2-methyl-1,4-naphthoquinone with glutathione. Chemico-Biol. Interact. 55:1985;177-184.
62. Schinder A.F., Olson E.C., Spitzer N.C., Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J. Neurosci. 16:1996;6125-6133.
63. Schutz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 80:1998;1-27.
64. Selemon L.D. Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease. Schizophr. Bull. 27:2001;349-377.
65. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 52:1995;805-818.
66. Selemon L.D., Rajkowska G., Goldman R.P.S. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 392:1998;402-412.
67. Seyfried J., Soldner F., Schulz J.B., Klockgether T., Kovar K.A.et al. Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neurosci. Lett. 264:1999;1-4.
68. Shepherd G.M. The dendritic spine: a multifunctional integrative unit. J. Neurophysiol. 75:1996;2197-2210.
69. Shi Z.Z., Osei-Frimpong J., Kala G., Kala S.V., Barrios R.J., Habib G.M.et al. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5101-5106.
70. Shukitt-Hale B., Denisova N.A., Strain J.G., Joseph J.A. Psychomotor effects of dopamine infusion under decreased glutathione. Free Radic. Biol. Med. 23:1997;412-418.
71. Sies H. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 27:1999;916-921.
72. Sinet P.M., Heikkila R.E., Cohen G. Hydrogen peroxide production by rat brain in vivo. J. Neurochem. 34:1980;1421-1428.
73. Stella N., Pellerin L., Magistretti P.J. Modulation of the glutamate-evoked release of arachidonic acid from mouse cortical neurons: involvement of a pH-sensitive membrane phospholipase A2. J. Neurosci. 15:1995;3307-3317.
74. + channels, glutamate release, and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation. J. Neurosci. 16:1996;5004-5013.
75. Ublacker G.A., Johnson J.A., Siegel F.L., Mulcahy R.T. Influence of glutathione S-transferases on cellular glutathione determination by flow cytometry using monochlorobimane. Cancer Res. 51:1991;1783-1788.
76. Wayment H.K., Schenk J.O., Sorg B.A. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J. Neurosci. 21:2001;35-44.
77. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44:1987;660-669.
78. White R.J., Reynolds I.J. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J. Neurosci. 16:1996;5688-5697.
79. Yao J.K., Reddy R.D., van Kammen D.P. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol. Psychiatry. 45:1999;1512-1515.
80. Yolken R.H., Karlsson H., Yee F., Johnston-Wilson N.L., Torrey E.F. Endogenous retroviruses and schizophrenia. Brain Res., Brain Res. Rev. 31:2000;193-199.